Evidence map›Paper›PMID 32053687›Full record

ArticlePloS one2020

Antimicrobial activity of Ib-M peptides against Escherichia coli O157: H7.

Sergio Prada-Prada, Johanna Flórez-Castillo, Ana Farfán-García, Fanny Guzmán, Indira Hernández-Peñaranda

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Mini-Review: Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sergio Prada-PradaMaestría en Investigación en Enfermedades Infecciosas, Facultad de Ciencias de la Salud, Grupo de Investigación en Ciencias Básicas y Aplicadas para la sostenibilidad - CIBAS, Universidad de Santander, Bucaramanga, Colombia.
Johanna Flórez-CastilloDepartamento de Ciencias Naturales, Facultad de Ciencias Exactas, Naturales y Agropecuarias, Grupo de Investigación en Ciencias Básicas y Aplicadas para la sostenibilidad - CIBAS, Universidad de Santander, Bucaramanga, Colombia.ORCID 0000-0001-5321-553X
Ana Farfán-GarcíaPrograma de Bacteriología y Laboratorio Clínico, Facultad de Ciencias de la Salud, Grupo de Investigación en Manejo Clínico - CLINIUDES, Universidad de Santander, Bucaramanga, Colombia.
Fanny GuzmánLaboratorio de Síntesis de Péptidos, Núcleo de Biotecnología Curauma (NBC), Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Indira Hernández-PeñarandaDepartamento de Ciencias Naturales, Facultad de Ciencias Exactas, Naturales y Agropecuarias, Grupo de Investigación en Ciencias Básicas y Aplicadas para la sostenibilidad - CIBAS, Universidad de Santander, Bucaramanga, Colombia.ORCID 0000-0002-1305-8100

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new antimicrobial peptides has become an attractive alternative to conventional antibiotics due to the increasing rates of microbial drug resistance. Ib-M corresponds to a family of cationic synthetic peptides, 20 amino acids in length, that have shown inhibitory effect against the non-pathogenic strain Escherichia coli K-12. This work evaluated the antimicrobial potential of Ib-M peptides against the pathogenic E. coli O157: H7 using a reference strain and a clinical isolate. The Ib-M peptides showed antibacterial activity against both strains of E. coli O157: H7; the minimum inhibitory concentration of Ib-M peptides ranged from 1.6 to 12.5 μM and the minimum bactericidal concentration ranged from 3.7 to 22.9 μM, being Ib-M1 and Ib-M2 the peptides that presented the highest inhibitory effect. Time-kill kinetics assay showed a reduction of the bacterial population by more than 95% after 4 hours of exposure to 1xMIC of Ib-M1. Low cytotoxicity was observed in VERO cells with 50% cytotoxic concentration in the range from 197.5 to more than 400 μM. All peptides showed a random structure in hydrophilic environments, except Ib-M1, and all of them transitioned to an α-helical structure when the hydrophobicity of the medium was increased. In conclusion, these findings support the in vitro antimicrobial effect of Ib-M peptides against the pathogenic bacteria E. coli O157: H7 and prove to be promising molecules for the development of new therapeutic alternatives.

Indexed as

AnimalsAnti-Bacterial AgentsChlorocebus aethiopsDrug Resistance, MicrobialEscherichia coli O157Microbial Sensitivity TestsVero CellsAnti-Bacterial Agents

Identifiers

PMID32053687
PMCPMC7018034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.